AA amyloidosis – Benefits and prospects of IL-6 inhibitors

References

• Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002;46(10):2571–3.
   PubMedGoogle Scholar
• Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B. Anti-tumor necrosis α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow up report of tolerability and efficacy. Arthritis Rheum. 2003;48(7):2019–24.
   PubMedGoogle Scholar
• Kuroda T, Wada Y, Kobayashi D, Murakami S, Sakai T, Hirose S. Effective anti-TNF-α therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol. 2009;36(11):2409–15.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2010;29(12):1395–401.
   PubMed Web of Science ®Google Scholar
• Fernández-Nebro A, Olivé A, Castro MC, Varela AH, Riera E, Irigoyen MV, et al. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010;123(5):454–61.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54(9):2997–3000.
   PubMedGoogle Scholar
• Sato H, Sakai T, Sugaya T, Otaki Y, Aoki K, Ishii K, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009;28(9):1113–16.
   PubMed Web of Science ®Google Scholar
• Magro-Checa C, Navas-Parejo Casado A, Borrego-Garcia E, Raya-Alvarez E, Rosales-Alexander JL, Salvatierra J, et al. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis. Amyloid. 2011;18(4):235–9.
   PubMed Web of Science ®Google Scholar
• Inoue D, Arima H, Kawanami C, Takiuchi Y, Nagano S, Kimura T, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid A deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010;29(10):1195–7.
   PubMed Web of Science ®Google Scholar
• Nishida S, Hagihara K, Shima Y, Kawai M, Kuwahara Y, Arimitsu J, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009;68(7):1235–6.
   PubMed Web of Science ®Google Scholar
• Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Jouyama K, et al. Successful tocilizumab treatment in a patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011;21(2):215–18.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24:137–43.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Yamada T, Ueda M, Ando Y. First nationwide survey of 199 patients with amyloid A amyloidosis in Japan. Internal Med. 2018. doi:10.2169/internalmedicine.1099-18.
   Web of Science ®Google Scholar
• Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999;37:381–8.
   PubMed Web of Science ®Google Scholar
• Okuda Y. Amyloid A amyloidosis complicating rheumatoid arthritis. Stomach Intest. 2014;49:335–43 [article in Japanese].
   Google Scholar
• Liepnieks JJ, Kluve-Beckerman B, Benson MD. Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim Biophys Acta. 1995;1270:81–6.
   PubMed Web of Science ®Google Scholar
• Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4(6):1083–7.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Yamada T, Takasugi K, Takeda M, Nanba S, Onishi M, et al. Serum amyloid A (SAA)1, SAA2 and apolipoprotein E isotype frequencies in rheumatoid arthritis patients with AA amyloidosis. Ryumachi. 1999;39:3–10 [article in Japanese].
   PubMedGoogle Scholar
• Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet. 1999;105(4):360–6.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):43–9.
   PubMed Web of Science ®Google Scholar
• Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998;5:262–5.
   PubMed Web of Science ®Google Scholar
• Hsu HC, Zhou T, Yang PA, Herrera GA, Mountz JD. Increased acute-phase response and renal amyloidosis in aged CD2-fas-transgenic mice. J Immunol. 1997;158(12):5988–96.
   PubMed Web of Science ®Google Scholar
• Yokota T, Ishihara T, Kawano H, Takahashi M, Fujinaga Y, Uchino F. Amyloid enhancing factor (AEF) in the aging mouse. Virchows Arch A Pathol Anat Histopathol. 1989;414(6):511–14.
   PubMedGoogle Scholar
• Okuda Y, Yamada T, Matsuura M, Takasugi K, Goto M. Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid. 2011;18(3):108–11.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358(9275):24–9.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–71.
   PubMed Web of Science ®Google Scholar
• Ravid M, Shapira J, Lang R, Kedar I. Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis. Ann Rheum Dis. 1982;41(6):587–92.
   PubMed Web of Science ®Google Scholar
• Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butrimiene I, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356(23):2349–60.
   PubMed Web of Science ®Google Scholar
• Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35(2):441–6.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kumon Y, Hirata S, Takaoka H. Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(4):501–8.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314(2):363–9.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, et al. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells. 2005;10(11):1051–63.
   PubMed Web of Science ®Google Scholar